IN2014DN05972A - - Google Patents

Info

Publication number
IN2014DN05972A
IN2014DN05972A IN5972DEN2014A IN2014DN05972A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A IN 5972DEN2014 A IN5972DEN2014 A IN 5972DEN2014A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A
Authority
IN
India
Prior art keywords
diseases associated
present
glucose metabolism
therapeutic agent
abnormal glucose
Prior art date
Application number
Inventor
Ichiro Hisatome
Shunsuke Tsujimoto
Takashi Shirakura
Shinya Hiramitsu
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of IN2014DN05972A publication Critical patent/IN2014DN05972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The purpose of the present invention is to provide a novel therapeutic agent or a novel prophylactic agent for diseases associated with abnormal glucose metabolism. The present invention is a therapeutic agent or a prophylactic agent for diseases associated with abnormal glucose metabolism which comprises a 2 phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
IN5972DEN2014 2012-01-27 2013-01-25 IN2014DN05972A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (en) 2012-01-27 2013-01-25 Therapeutic agent for diabetes

Publications (1)

Publication Number Publication Date
IN2014DN05972A true IN2014DN05972A (en) 2015-06-26

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5972DEN2014 IN2014DN05972A (en) 2012-01-27 2013-01-25

Country Status (15)

Country Link
US (1) US20150005506A1 (en)
EP (1) EP2808018B1 (en)
JP (1) JP5924699B2 (en)
KR (1) KR20140134266A (en)
CN (1) CN104066430A (en)
AR (1) AR089812A1 (en)
AU (1) AU2013212865A1 (en)
BR (1) BR112014017902A2 (en)
CA (1) CA2862602A1 (en)
HK (1) HK1201209A1 (en)
IN (1) IN2014DN05972A (en)
MX (1) MX2014008484A (en)
RU (1) RU2014134845A (en)
TW (1) TW201334779A (en)
WO (1) WO2013111870A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628673A (en) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 Nitrile benzene thiazolecarboxamide type compound containing tert-butylamidine structure and application thereof
CN104610188B (en) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 Itrile group benzene thiazole carboxylic acid amides's compounds containing benzene carbon amidine structure, its preparation and purposes
CN104610190B (en) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 One class contains halogenophenyl thiazole carboxylic acid amides's compounds and the purposes of cyclopropyl amidine structure
CN104628671B (en) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 Containing oil of mirbane thiazole carboxylic acid amides compounds and the purposes of benzene carbon amidine structure
CN104628672A (en) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 Alkoxyphenylthiazole carboxylic acid amide compounds containing phenylamidine structures and application
KR102473677B1 (en) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 Liquid crystal display
ES2842577T3 (en) 2016-02-19 2021-07-14 Nezu Life Science Co Ltd Therapeutic or prophylactic drug for dementia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513379T3 (en) * 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazole derivatives and pharmaceutical compositions containing them
HUP9902721A2 (en) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Concentrated fabric softening composition and highly unsaturated fabric softener compound therefor
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
WO2007018687A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
JP2008506785A (en) * 2004-07-21 2008-03-06 フロリダ大学 リサーチファウンデーション インコーポレイティッド Compositions and methods for the treatment and prevention of insulin resistance
WO2007019153A2 (en) 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2630639A1 (en) * 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (en) 2006-02-13 2007-08-23 Hiroshima Univ Agent for preventing/treating glucose tolerance dysfunction, type ii diabetes, hyperlipemia, metabolic syndrome, visceral fat obesity, fatty liver or non-alcoholic fatty hepatitis
RU2508099C2 (en) 2006-11-13 2014-02-27 Такеда Фармасьютикалз Норт Америка, Инк. Methods for preserving renal function with using xanthine oxidoreductase
CN103058944B (en) * 2007-11-27 2015-08-05 亚德生化公司 Regulate the compound of blood uric acid levels
CN102015726B (en) * 2008-03-31 2014-07-23 C&C新药研究所 Heterocyclic derivatives
MX2010011603A (en) * 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid.
JP5820269B2 (en) * 2008-05-22 2015-11-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Method for treating hyperuricemia using SGLT2 inhibitor and composition containing SGLT2 inhibitor
CN102256488A (en) * 2008-10-19 2011-11-23 理查德·J·约翰逊 Therapeutic compositions and methods for treating chronic kidney disease associated with a metabolic imbalance
EP2470268A4 (en) * 2009-08-24 2012-12-26 Wound Man Pty Ltd Purine-targeted diagnosis and therapy of wounds
EP2582812B1 (en) * 2010-06-16 2018-01-24 Takeda Pharmaceuticals U.S.A., Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
WO2011162390A1 (en) * 2010-06-25 2011-12-29 帝人ファーマ株式会社 Sustained-release therapeutic agent for hypertension and renal dysfunction

Also Published As

Publication number Publication date
US20150005506A1 (en) 2015-01-01
TW201334779A (en) 2013-09-01
KR20140134266A (en) 2014-11-21
HK1201209A1 (en) 2015-08-28
CA2862602A1 (en) 2013-08-01
BR112014017902A2 (en) 2017-08-22
EP2808018B1 (en) 2018-03-14
AU2013212865A1 (en) 2014-08-14
AR089812A1 (en) 2014-09-17
WO2013111870A1 (en) 2013-08-01
MX2014008484A (en) 2014-10-14
EP2808018A4 (en) 2015-07-15
CN104066430A (en) 2014-09-24
EP2808018A1 (en) 2014-12-03
JPWO2013111870A1 (en) 2015-05-11
JP5924699B2 (en) 2016-05-25
RU2014134845A (en) 2016-03-20

Similar Documents

Publication Publication Date Title
PH12017501426A1 (en) Derivatives of betulin
PH12015502839A1 (en) Antiviral compounds
MX2016006336A (en) Pyrazolopyrimidine compounds.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
IN2015MN00404A (en)
AU2012214029A8 (en) Rorgammat inhibitors
MX2015003594A (en) Therapeutic or prophylactic agent for tumor lysis syndrome.
MX2015017861A (en) Benzothiophene derivatives as estrogen receptor inhibitors.
IN2014DN05972A (en)
MX2015005286A (en) Process for preparing bile acid derivatives.
MY183312A (en) Pharmaceutical formulation
MX2015010971A (en) Novel pyrazole derivative.
JO3530B1 (en) 1,4-disubstituted pyridazine analogs there of and methods for treating smn-deficiency-related conditions
IN2014MN02106A (en)
IN2015DN00185A (en)
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
MY187718A (en) Pharmaceutical formulations
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MX364400B (en) Tetracycline compounds.
WO2011123536A8 (en) Polycyclic tetracycline compounds
MX2021010046A (en) A new therapeutical composition containing apomorphine as active ingredient.
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
IN2014CN04449A (en)
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MX362919B (en) Bicyclo [2.2.1] acid gpr120 modulators.